<DOC>
	<DOCNO>NCT01576484</DOCNO>
	<brief_summary>This phase 2 , open-label extension study ass long-term safety efficacy REGN727 ( SAR236553 ) administer subcutaneous ( SC ) injection patient previously participate R727-CL-1003 study .</brief_summary>
	<brief_title>Open-Label Extension Study R727-CL-1003 Evaluate Long-Term Safety Efficacy REGN727 ( SAR236553 ) Patients With Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Key Inclusion Criteria 1 . Prior participation successful completion R727CL1003 study . 2 . Patients must stable daily statin regimen least 3 week prior entry study 3 . A negative urine pregnancy screening/baseline visit woman childbearing potential Key Exclusion Criteria 1 . Reported drugrelated SAE drugrelated clinical laboratory AE R727CL1003 study result early termination withdrawal 2 . Significant protocol deviation R727CL1003 , noncompliance investigator patient 3 . LDL apheresis within 12 month screening/baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>